A detailed history of Acadian Asset Management LLC transactions in Fibrogen Inc stock. As of the latest transaction made, Acadian Asset Management LLC holds 3,905,350 shares of FGEN stock, worth $1.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,905,350
Previous 3,364,719 16.07%
Holding current value
$1.37 Million
Previous $3 Million 48.05%
% of portfolio
0.0%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.33 - $1.26 $178,408 - $681,195
540,631 Added 16.07%
3,905,350 $1.56 Million
Q2 2024

Aug 06, 2024

BUY
$0.89 - $2.36 $766,160 - $2.03 Million
860,854 Added 34.38%
3,364,719 $3 Million
Q1 2024

May 10, 2024

BUY
$0.73 - $2.73 $25,504 - $95,378
34,937 Added 1.42%
2,503,865 $5.88 Million
Q4 2023

Feb 13, 2024

BUY
$0.38 - $0.91 $324,456 - $776,988
853,834 Added 52.87%
2,468,928 $2.19 Million
Q3 2023

Nov 13, 2023

BUY
$0.79 - $2.83 $1.28 Million - $4.57 Million
1,615,094 New
1,615,094 $1.39 Million
Q1 2022

May 12, 2022

SELL
$12.02 - $16.79 $16,828 - $23,506
-1,400 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$9.93 - $15.39 $13,902 - $21,546
1,400 New
1,400 $19,000
Q3 2021

Nov 12, 2021

SELL
$10.18 - $26.64 $214,808 - $562,130
-21,101 Closed
0 $0
Q2 2021

Aug 11, 2021

BUY
$18.57 - $35.68 $83,472 - $160,381
4,495 Added 27.07%
21,101 $562,000
Q1 2021

May 11, 2021

BUY
$31.0 - $55.72 $496,031 - $891,575
16,001 Added 2644.79%
16,606 $576,000
Q4 2020

Feb 11, 2021

BUY
$37.09 - $48.97 $22,439 - $29,626
605 New
605 $22,000
Q2 2020

Aug 12, 2020

SELL
$32.57 - $42.83 $21,691 - $28,524
-666 Closed
0 $0
Q1 2020

May 11, 2020

SELL
$23.3 - $45.96 $67,127 - $132,410
-2,881 Reduced 81.22%
666 $23,000
Q4 2019

Feb 06, 2020

BUY
$34.58 - $48.06 $122,655 - $170,468
3,547 New
3,547 $152,000

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.